IM Cannabis is one of the most internationally visible Israeli cannabis companies — and, in 2026, one of the most clearly in transition. Listed on Nasdaq under IMCC, it has spent the past year reshaping itself around two markets, Israel and Germany, and is now divesting the European side to refocus. This profile explains the company and the pivot.
This guide is informational and is not investment advice. Figures and corporate actions are point-in-time; verify against the company's filings.
What IM Cannabis is
IM Cannabis Corp. (Nasdaq: IMCC) is a medical cannabis operator that has served patients in both Israel and Germany. For 2025 it reported revenue of C$54.7 million, with over 134% growth in its German business and positive operating cash flow (IM Cannabis IR). Germany — Europe's most important medical cannabis market — had been the company's growth engine.
The European sale
The defining move came in 2026. IM Cannabis entered a letter of intent to sell its European business, including its German subsidiary Adjupharm GmbH, in a transaction expected to reduce debt by about C$10.5 million (PR Newswire).
One feature of the deal demands scrutiny: it is a related-party transaction. The buyer, Slil.com Holding Ltd., is an Israeli entity beneficially owned and controlled by IM Cannabis's own CEO, Oren Shuster (InvestorIdeas). Related-party deals require special oversight and regulatory approval precisely because the buyer and the seller's management overlap, and observers should watch how independent directors and shareholders treat the terms.
The strategic refocus
Selling the European operations effectively narrows IM Cannabis back to Israel, the market where it began. At the same time, the company has signalled it is evaluating opportunities to enter the U.S. cannabis market (InvestorIdeas). The strategic logic is debt reduction now, with optionality on a larger future market — though a U.S. move would put the company into a very different and federally complex regulatory environment.
How to read it
IM Cannabis is a useful counterpoint to InterCure. Where InterCure has pursued scale and vertical integration to profitability, IM Cannabis is restructuring — shedding a fast-growing but capital-hungry European arm to shore up its balance sheet and concentrate on its home market. For anyone tracking the sector, it illustrates a recurring theme in Israeli cannabis: the gap between revenue growth and sustainable profit, and the hard choices companies make to close it.
For the broader field, see our Companies hub; for the trade backdrop, Israel's cannabis export industry; and for the listed-equity view, investing in Israeli cannabis stocks.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Companies.